NanHua Bio-medicine Co., Ltd. completed the acquisition of 54% stake in Hunan ProMab Biotechnologies Co., Ltd. from Hunan Publishing Investment Holding Group Co., Ltd., Shenzhen Faith Chengfu Equity Investment Partnership Enterprise (LP) and Yi Yinsha.
January 22, 2018
Share
NanHua Bio-medicine Co., Ltd. (SZSE:000504) agreed to acquire 54% stake in Hunan ProMab Biotechnologies Co., Ltd. from Hunan Publishing Investment Holding Group Co., Ltd., Shenzhen Faith Chengfu Equity Investment Partnership Enterprise (LP) and Yi Yinsha for CNY 51.3 million on September 25, 2017. On December 2, 2017, an agreement was signed. NanHua Bio-medicine Co., Ltd. will acquire 40% stake from Hunan Publishing Investment Holding Group Co., Ltd., 10% stake from Shenzhen Faith Chengfu Equity Investment Partnership Enterprise (LP) and 4% stake from Yi Yinsha. Prior to the transaction, Hunan Publishing Investment Holding Group Co., Ltd. held 55% stake, Shenzhen Faith Chengfu Equity Investment Partnership Enterprise (LP) held 10% stake and Yi Yinsha held 4% stake.
Hunan ProMab Biotechnologies Co., Ltd. reported total assets of CNY 24.55 million and total shareholders’ equity of CNY 19.28 million as at December 31, 2016. Hunan ProMab Biotechnologies Co., Ltd. reported operating revenues of CNY 24.12 million, operating profit of CNY 1.01 million and net profit of CNY 0.84 million in 2016. The committee meeting of Hunan Publishing Investment Holding Group Co., Ltd. approved the transaction on September 18, 2017. The partner of Shenzhen Faith Chengfu Equity Investment Partnership Enterprise (LP) approved the transaction on September 20, 2017. The shareholders’ of Hunan ProMab Biotechnologies Co., Ltd. approved the transaction on September 25, 2017. The Board of Directors of NanHua Bio-medicine Co., Ltd. approved the transaction on December 2, 2017. The shareholders of NanHua Bio-medicine Co., Ltd. approved the transaction on December 19, 2017. China Merchants Securities Co.,Ltd. (SHSE:600999) acted as the financial advisor, Qin Qiao and Guo Xin of Grandway Law Offices acted as the legal advisors and Liu Jie and Chen Lifang of Ruihua Certified Public Accountants, LLP acted as the accountants to NanHua Bio-medicine Co., Ltd.
NanHua Bio-medicine Co., Ltd. (SZSE:000504) completed the acquisition of 54% stake in Hunan ProMab Biotechnologies Co., Ltd. from Hunan Publishing Investment Holding Group Co., Ltd., Shenzhen Faith Chengfu Equity Investment Partnership Enterprise (LP) and Yi Yinsha on January 22, 2018.
Landfar Bio medicine Co Ltd is a China-based company mainly engaged in the biomedical and energy conservation & environmental protection business. The Companyâs biomedical business includes stem cell storage and technical services, stem cell treatment research, medical instrument purchasing & sales. The Companyâs energy conservation & environmental protection business includes energy management company (EMC) contract energy management, build-transfer (BT), product sales, and sewage treatment. The Company is involved in other businesses related to aid and build project. The Company mainly conducts businesses within the domestic market.
NanHua Bio-medicine Co., Ltd. completed the acquisition of 54% stake in Hunan ProMab Biotechnologies Co., Ltd. from Hunan Publishing Investment Holding Group Co., Ltd., Shenzhen Faith Chengfu Equity Investment Partnership Enterprise (LP) and Yi Yinsha.
LANDFAR BIO-MEDICINE CO., LTD 
